- What is cancer?
- What is bone metastasis?
- What are the key statistics about bone metastases?
- What are the risk factors for bone metastases?
- Do we know what causes bone metastases?
- Can bone metastases be prevented?
- How are bone metastases diagnosed?
- How are bone metastases treated?
- Systemic treatments for bone metastases
- Local treatments for bone metastases
- Pain medicines for bone metastases
- Clinical trials for bone metastases
- Complementary and alternative therapies for bone metastases
- Treating problems caused by bone metastases
- More treatment information about bone metastases
- What should you ask your doctor about bone metastases?
- What happens after treatment of bone metastases?
- What`s new in bone metastasis research and treatment?
- Additional resources for bone metastases
- References: Bone metastases detailed guide
References: Bone metastases detailed guide
Bamias A, Kastritis E, Bamia C. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:8580−8587.
Bartels RH, van der Linden YM, van der Graaf WT. Spinal extradural metastasis: Review of current treatment options. CA Cancer J Clin. 2008;58:245−259.
Basile A, Giuliano G, Scuderi V, et al. Cementoplasty in the management of painful extraspinal bone metastases: Our experience. Radiol Med. 2008;113:1018−1028.
Belfiore G, Tedeschi E, Ronza FM, et al. Radiofrequency ablation of bone metastases induces long-lasting palliation in patients with untreatable cancer. Singapore Med J. 2008;49:565−570.
Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59−69.
Callstrom MR, Charboneau JW, Goetz MP, et al. Image-guided ablation of painful metastatic bone tumors: A new and effective approach to a difficult problem. Skeletal Radiol. 2006;35:1−15.
Chow E, Finkelstein JA, Sahgal A, Coleman RE. Metastatic cancer to the bone. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011: 2192−2204.
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s−6249s.
Coleman RE, Guise TA, Lipton A, et al. Advancing treatment for metastatic bone cancer: Consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008;14:6387−6395.
Coleman RE, Holen I. Bone metastasis. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff's Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008: 845−871.
Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6:392−400.
Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol. 2009;182:509−515.
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 2011;377:813−822.
Hartsell WF, Scot CB, Watkins D. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97:798−804.
Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125−1132.
Kenan S, Mechanick JI. Skeletal complications. In Kufe DW, Bast RC, Hait WN, et al (eds) Cancer Medicine, 7th ed, Lewiston NY: BC Decker; 2006: 2085−2094.
Leeming DJ, Hegele A, Byrjalsen I, et al. Biochemical markers for monitoring response to therapy: Evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev. 2008;17:1269−1276.
Lipton A. Advances in treating metastatic bone cancer: Future treatment of bone metastases. Clin Cancer Res. 2006;12:6305s−6308s.
Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008;14:6690−6696.
Mundy G. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature Reviews Cancer. 2002;2:584−593.
Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: A randomised trial. Lancet. 2005;366:643−648.
Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;(3):CD003474.
Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20:137−145.
Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735−1744.
Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol. 2010;28:5132−5139.
Last Medical Review: 05/03/2012
Last Revised: 05/03/2012